Clinical Trials Directory

Trials / Unknown

UnknownNCT06060262

The Alterations of Metabolic Adipo-myokines and Body Composition in End Stage Lung Cancer

The Clinical Significance of Metabolic Adipo-myokines and Alterations of Body Composition in Patients With End Stage Lung Cancer

Status
Unknown
Phase
Study type
Observational
Enrollment
600 (estimated)
Sponsor
Chang Gung Memorial Hospital · Academic / Other
Sex
All
Age
20 Years – 100 Years
Healthy volunteers
Not accepted

Summary

The investigators conduct this prospective study and wish to elucidate the association of serial change of body composition, serum adipo-myokines and adverse effect of chemotherapy and lung cancer prognosis

Detailed description

Recently, the skeletal muscle was viewed as having biochemical function in additional to traditional biomechanical function. What's more important is that muscles could synthesize and release adipo-myokines during contraction. The adipo-myokines can affect muscle regeneration, muscle atrophy, muscle mass, autophagy, fatty acid oxidation and mitochondrial biosynthesis.Studies have also found that exercise can promote the function of macrophages and regulate both pro-inflammatory and anti-inflammatory phenotypes, helping the body to establish a stable immune balance. Since body composition can illustrate malnutrition status and cancer cachexia present, and body composition can be affected by serum adipo-myokines level. Therefore, the investigators conduct this study and wish to see the association of serial body composition and serum adipo-myokines changes with lung cancer clinical outcomes and adverse effect of any anti-cancer regimen.

Conditions

Timeline

Start date
2023-02-02
Primary completion
2025-11-30
Completion
2025-11-30
First posted
2023-09-29
Last updated
2023-09-29

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT06060262. Inclusion in this directory is not an endorsement.